Africa and Middle East Cardiovascular Epidemiological Study (ACE)
Prevalence of Cardiovascular Risk Factors in Patients Attending General Practice Clinics in Selected Countries in the Africa and The Middle East Region
Sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
A observational or N/A phase clinical study on Diabetes Mellitus and Dyslipidemia, this trial is completed. The trial is conducted by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. and has accumulated 13 data snapshots since 2011. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.
Status Flow
Change History
13 versions recorded-
Nov 2025 — Present [monthly]
Completed
-
Sep 2025 — Nov 2025 [monthly]
Completed
-
Sep 2024 — Sep 2025 [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Dec 2021 — Jul 2024 [monthly]
Completed
▶ Show 8 earlier versions
-
Mar 2021 — Dec 2021 [monthly]
Completed
-
Jan 2021 — Mar 2021 [monthly]
Completed
-
Nov 2020 — Jan 2021 [monthly]
Completed
-
Jun 2018 — Nov 2020 [monthly]
Completed
-
May 2018 — Jun 2018 [monthly]
Completed
-
Apr 2018 — May 2018 [monthly]
Completed
Phase: NA → None
-
Aug 2017 — Apr 2018 [monthly]
Completed NA
-
Jan 2017 — Aug 2017 [monthly]
Completed NA
First recorded
Jul 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Abu Dhabi, United Arab Emirates , Abuja, FCT, Nigeria , Abuja, Garki, Nigeria , Accra, Ghana , Adailiya, Kuwait , Al Ain City, United Arab Emirates , Al Faḩāḩīl, Kuwait , Alexandria, Egypt , Algiers, Algeria , Amman, Jordan and 61 more locations